What is T2DM Phase III REWIND Study (Dulaglutide)?

Category: Others

true

Generic name: Dulaglutide

This is a clinical trial evaluating the effect of dulaglutide (also known as LY2189265), an injectable antidiabetic, on major cardiovascular events when compared to placebo in subjects with noninsulin dependent diabetes (also known as type 2 diabetes). Clinical Trial Identifier: NCT01394952

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 0
Mild 0
None 2

Commonly reported side effects and conditions associated with T2DM Phase III REWIND Study (Dulaglutide)

Side effect Patients

Dosages

Based on patients currently taking T2DM Phase III REWIND Study (Dulaglutide)

Dosage Patients
0.5 mL weekly 1

Duration

Currently taking T2DM Phase III REWIND Study (Dulaglutide)

Duration Patients
2 - 5 years 1
Adherence
Adherence Evaluations
Always 2
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 1
A little hard to take 1
Not at all hard to take 0
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 1
Not specified 1
Last updated:
There are no evaluations for T2DM Phase III REWIND Study (Dulaglutide).